Back to Search
Start Over
Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
- Source :
- Pharmacological Research
- Publication Year :
- 2021
-
Abstract
- Background Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. Objectives to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hospitalised with respiratory viral infections, including COVID-19, SARS, MERS and influenza. Methods We identified randomised trials published prior to July 28th, 2021. The Mantel-Haenszel random effects method and the Hartung and Knapp adjustment were used to obtain pooled estimates of treatment effect with 95% confidence intervals. Results No randomised trials of glucocorticoids for SARS, MERS or influenza reported relevant outcomes. We included eleven COVID-19 randomised trials (8109 patients). Overall, compared to placebo or standard care, glucocorticoids were not associated with a reduction of in-hospital mortality (p = 0.09). In a pre-specified sub-analysis, in-hospital mortality was reduced by 19% when follow-up was restricted to 14 days from randomisation (5/11 trials, 1329 patients, p = 0.02). With longer follow-up (9/11 trials, 7874 patients), administration of glucocorticoids was associated with a trend to benefit for those requiring mechanical ventilation (RR 0.86; 95% CI 0.57–1.27) but possible harm for those not receiving oxygen at randomisation (RR 1.27; 95% CI 1.00 – 1.61), an effect that was significantly different amongst subgroups (p = 0.0359). Glucocorticoids reduced the risk of worsening renal function by 37% (4/11 trials); reported rate of other cardiovascular complications was low. Conclusions Administration of systemic glucocorticoids to patients hospitalised with COVID-19 does not lower mortality overall but may reduce it in those requiring respiratory support and increase it in those who do not.<br />Graphical Abstract ga1
- Subjects :
- 030204 cardiovascular system & hematology
Severe Acute Respiratory Syndrome
Article
Dexamethasone
03 medical and health sciences
0302 clinical medicine
Glucocorticoid
Cardiovascular Disease
Influenza, Human
Humans
Meta-analysi
030212 general & internal medicine
Mortality
Steroid
Glucocorticoids
Randomized Controlled Trials as Topic
Pharmacology
Coronavirus Infection
SARS-CoV-2
COVID-19
3. Good health
COVID-19 Drug Treatment
Hospitalization
Meta-analysis
Cardiovascular Diseases
Steroids
Coronavirus Infections
Human
Subjects
Details
- ISSN :
- 10961186 and 10436618
- Volume :
- 176
- Database :
- OpenAIRE
- Journal :
- Pharmacological research
- Accession number :
- edsair.doi.dedup.....d7dd60fb4ed58a9830161f494a201943